KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Convertible Debt: 2011-2014

Historic Convertible Debt for Regeneron Pharmaceuticals (REGN) over the last 4 years, with Dec 2014 value amounting to $146.8 million.

  • Regeneron Pharmaceuticals' Convertible Debt fell 89.33% to $30.7 million in Q3 2015 from the same period last year, while for Sep 2015 it was $30.7 million, marking a year-over-year decrease of 89.33%. This contributed to the annual value of $146.8 million for FY2014, which is 54.18% down from last year.
  • According to the latest figures from FY2014, Regeneron Pharmaceuticals' Convertible Debt is $146.8 million, which was down 54.18% from $320.3 million recorded in FY2013.
  • In the past 5 years, Regeneron Pharmaceuticals' Convertible Debt ranged from a high of $320.3 million in FY2013 and a low of $146.8 million during FY2014.
  • Moreover, its 3-year median value for Convertible Debt was $296.5 million (2012), whereas its average is $254.5 million.
  • In the last 5 years, Regeneron Pharmaceuticals' Convertible Debt increased by 8.03% in 2013 and then tumbled by 54.18% in 2014.
  • Yearly analysis of 4 years shows Regeneron Pharmaceuticals' Convertible Debt stood at $275.0 million in 2011, then increased by 7.82% to $296.5 million in 2012, then grew by 8.03% to $320.3 million in 2013, then tumbled by 54.18% to $146.8 million in 2014.